Top-News

Mabvax Therapeutics Holdings News

Keine aktuellen Kursdaten verfügbar
WKN: A12BGC
ISIN: US55414P1084
Typ: Aktie

Mabvax Therapeutics Holdings News

17.08.16 - PR Newswire
MabVax Therapeutics Announces Uplisting to The Nasdaq Capital Market and $8.625 million Public Offering
MabVax Therapeutics Announces Uplisting to The Nasdaq Capital Market and $8.625 million Public Offering PR Newswire
18.07.16 - PR Newswire
MabVax Therapeutics Initiates Patient Enrollment in a Phase I Trial for a New Diagnostic Imaging Product for Pancreatic Cancer
MabVax Therapeutics Initiates Patient Enrollment in a Phase I Trial for a New Diagnostic Imaging Product for Pancreatic Cancer PR Newswire
13.06.16 - PR Newswire
MabVax Therapeutics Launches Second Investigational Site with Sarah Cannon Research Institute in Ongoing Phase I Clinical Trial to Evaluate New Treatment for Pancreatic Cancer
MabVax Therapeutics Launches Second Investigational Site with Sarah Cannon Research Institute in Ongoing Phase I Clinical Trial to Evaluate New Treatment for Pancreatic ...
07.06.16 - PR Newswire
MabVax Therapeutics Expands Patient Enrollment in Phase I Trial for Treatment of Pancreatic Cancer to Memorial Sloan Kettering Cancer Center
MabVax Therapeutics Expands Patient Enrollment in Phase I Trial for Treatment of Pancreatic Cancer to Memorial Sloan Kettering Cancer Center PR Newswire
19.05.16 - PR Newswire
MabVax Therapeutics' Antibody Discovery Platform and HuMab-5B1 Cancer Therapeutic Featured in Presentation at America's Antibody Congress
MabVax Therapeutics' Antibody Discovery Platform and HuMab-5B1 Cancer Therapeutic Featured in Presentation at America's Antibody Congress PR Newswire
16.05.16 - PR Newswire
MabVax Therapeutics' HuMab-5B1 Cancer Therapeutic Featured in Presentation at AACR Special Meeting on Pancreatic Cancer
MabVax Therapeutics' HuMab-5B1 Cancer Therapeutic Featured in Presentation at AACR Special Meeting on Pancreatic Cancer PR Newswire
18.04.16 - PR Newswire
MabVax Therapeutics' Fully Human Antibody Approach to Cancer Therapeutics and Imaging Featured in Three Presentations at AACR Annual Meeting in New Orleans
MabVax Therapeutics' Fully Human Antibody Approach to Cancer Therapeutics and Imaging Featured in Three Presentations at AACR Annual Meeting in New Orleans PR Newswire
15.04.16 - PR Newswire
MabVax Therapeutics Holdings Hires Paul Resnick, M.D. as Chief Business Officer
MabVax Therapeutics Holdings Hires Paul Resnick, M.D. as Chief Business Officer PR Newswire
21.03.16 - PR Newswire
MabVax Therapeutics Initiates Phase I Trial of HuMab-5B1 for Treatment of Pancreatic Cancer
MabVax Therapeutics Initiates Phase I Trial of HuMab-5B1 for Treatment of Pancreatic Cancer HuMab-5B1 is a Fully Human Antibody With Remarkable Preclinical Specificity and ...
10.03.16 - PR Newswire
MabVax Therapeutics to Present at the ROTH Conference
MabVax Therapeutics to Present at the ROTH Conference PR Newswire
25.02.16 - PR Newswire
MabVax Therapeutics Holdings Announces New Board Member
MabVax Therapeutics Holdings Announces New Board Member PR Newswire
03.02.16 - PR Newswire
MabVax Therapeutics to Present at BIO CEO & Investor Conference
MabVax Therapeutics to Present at BIO CEO & Investor Conference PR Newswire
01.02.16 - PR Newswire
MabVax Therapeutics Receives FDA Authorization for Phase I Clinical Trial with 89Zr-HuMab-5B1 as PET Imaging Agent for Pancreatic Cancer
MabVax Therapeutics Receives FDA Authorization for Phase I Clinical Trial with 89Zr-HuMab-5B1 as PET Imaging Agent for Pancreatic Cancer Phase I Trials with HuMab-5B1 as ...
19.01.16 - PR Newswire
MabVax Therapeutics Holdings Executes a Debt Facility for up to $10 million
MabVax Therapeutics Holdings Executes a Debt Facility for up to $10 million PR Newswire
06.01.16 - PR Newswire
MabVax Therapeutics Files IND for a Phase I Clinical Trial with 89Zr-HuMab-5B1
MabVax Therapeutics Files IND for a Phase I Clinical Trial with 89Zr-HuMab-5B1 Enrollment in Trial with New PET Imaging Agent Expected to Begin in Early 2016 PR Newswire
01.12.15 - PR Newswire
MabVax Therapeutics Files IND for Phase I Clinical Trial with HuMab 5B1 as a Therapeutic for Pancreatic Cancer
MabVax Therapeutics Files IND for Phase I Clinical Trial with HuMab 5B1 as a Therapeutic for Pancreatic Cancer Enrollment Expected to Begin in Early 2016 PR Newswire
03.11.15 - PR Newswire
MabVax Therapeutics Completes Manufacturing of HuMab 5B1 for Upcoming Phase I Clinical Trials
MabVax Therapeutics Completes Manufacturing of HuMab 5B1 for Upcoming Phase I Clinical Trials PR Newswire
21.10.15 - PR Newswire
MabVax Therapeutics HuMab 5B1 Antibody Featured in Five Presentations at the World Molecular Imaging Congress
MabVax Therapeutics HuMab 5B1 Antibody Featured in Five Presentations at the World Molecular Imaging Congress PR Newswire
20.10.15 - PR Newswire
MabVax Therapeutics to Hold Investor Webcast and Conference Call on Thursday, October 22nd at 11:00 am EDT
MabVax Therapeutics to Hold Investor Webcast and Conference Call on Thursday, October 22nd at 11:00 am EDT PR Newswire
30.09.15 - PR Newswire
MabVax Therapeutics Holdings, Inc. Announces Pricing of Public Offering
MabVax Therapeutics Holdings, Inc. Announces Pricing of Public Offering PR Newswire

Newssuche

Videos

08:40 Uhr +9,05%
Technical Trading: Gold Long freitags
Gold Long Typ: Turbo Open End WKN: NG8DB8 Hebel: 27 Laufzeit: OpenEnd Einstieg: Market ... Mehr »